Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
REVELATION BIOSCIENCES, INC. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at gross proceeds of approximately $6.2 million (effective 2024-02-01).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Roth Capital Partners, LLC
- Value
- gross proceeds of approximately $6.2 million
- Effective
- 2024-02-01
Exact text from the filing
On February 1, 2024, Revelation Biosciences, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”)
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
REVELATION BIOSCIENCES, INC. entered into Purchase Agreement with certain purchasers valued at gross proceeds of approximately $6.2 million (effective 2024-02-01).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain purchasers
- Value
- gross proceeds of approximately $6.2 million
- Effective
- 2024-02-01
Exact text from the filing
On February 1, 2024, Revelation Biosciences, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of (i) 128,470 shares of its common stock, par value $0.001 per share (the “Common Stock”) and pre-funded warrants to purchase 1,236,530 shares of Common Stock (the “Pre-Funded Warrants”) and (ii) accompanying two warrants to purchase 2,730,000 shares of Common Stock (the “Class D Common Stock Warrants”) at a combined offering price of $4.53 per share of Common Stock and associated two Class D Common Stock Warrants, or $4.5299 per Pre-Funded Warrant and associated two Class D Common Stock Warrants, resulting
View on SEC.gov